ARCT vs. MBX

Last updated Jun 9, 2026

ARCT (Arcturus Therapeutics Holdings Inc.) and MBX (MBX Biosciences, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, ARCT returned -44.33% vs 155.06% for MBX. At a 0.25 correlation, their price movements are largely independent.

Performance

ARCT vs. MBX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcturus Therapeutics Holdings Inc. (ARCT) and MBX Biosciences, Inc (MBX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ARCT achieves a 16.15% return, which is significantly higher than MBX's -8.05% return.

ARCT

• 1D: -2.47%
• 1M: -22.78%
• YTD: 16.15%
• 6M: -4.43%
• 1Y: -44.33%
• 3Y*: -36.26%
• 5Y*: -26.90%
• 10Y*: —

MBX

• 1D: -4.23%
• 1M: -29.21%
• YTD: -8.05%
• 6M: -7.61%
• 1Y: 155.06%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ARCT vs. MBX - Yearly Performance Comparison

	2026 (YTD)	2025	2024
ARCT Arcturus Therapeutics Holdings Inc.	16.15%	-63.88%	-18.22%
MBX MBX Biosciences, Inc	-8.05%	71.13%	-22.07%

Correlation

The correlation between ARCT and MBX is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.24
Correlation (All Time) Calculated using the full available price history since Sep 16, 2024	0.25

Fundamentals

Market Cap ARCT : $202.36M MBX : $1.35B
EPS ARCT : -$1.81 MBX : -$2.30
PB Ratio ARCT : 1.06 MBX : 3.09
Total Revenue (TTM) ARCT : $46.80M MBX : $0.00
Gross Profit (TTM) ARCT : $40.72M MBX : -$160.00K
EBITDA (TTM) ARCT : -$84.61M MBX : -$96.31M

Return for Risk

ARCT vs. MBX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARCT

ARCT Risk / Return Rank: 25
ARCT Sharpe Ratio Rank: 21
ARCT Sortino Ratio Rank: 28
ARCT Omega Ratio Rank: 27
ARCT Calmar Ratio Rank: 21
ARCT Martin Ratio Rank: 26

MBX

MBX Risk / Return Rank: 85
MBX Sharpe Ratio Rank: 77
MBX Sortino Ratio Rank: 88
MBX Omega Ratio Rank: 84
MBX Calmar Ratio Rank: 89
MBX Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARCT vs. MBX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and MBX Biosciences, Inc (MBX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARCT	MBX	Difference
Sharpe ratio: Return per unit of total volatility	-0.48	1.17	-1.65
Sortino ratio: Return per unit of downside risk	-0.15	2.91	-3.06
Omega ratio: Gain probability vs. loss probability	0.98	1.33	-0.35
Calmar ratio: Return relative to maximum drawdown	-0.60	4.15	-4.75
Martin ratio: Return relative to average drawdown	-0.83	7.99	-8.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARCT vs. MBX - Sharpe Ratio Comparison

The current ARCT Sharpe Ratio is -0.48, which is lower than the MBX Sharpe Ratio of 1.17. The chart below compares the historical Sharpe Ratios of ARCT and MBX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ARCT	MBX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.48	1.17	-1.65
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.13	0.11	-0.24

Drawdowns

ARCT vs. MBX - Drawdown Comparison

The maximum ARCT drawdown since its inception was -95.23%, which is greater than MBX's maximum drawdown of -77.71%. Use the drawdown chart below to compare losses from any high point for ARCT and MBX.

Drawdown Indicators

	ARCT	MBX	Difference
Max Drawdown Largest peak-to-trough decline	-95.23%	-77.71%	-17.52%
Max Drawdown (1Y) Largest decline over 1 year	-74.53%	-37.60%	-36.93%
Max Drawdown (3Y) Largest decline over 3 years	-86.71%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-89.87%	—	—
Current Drawdown Current decline from peak	-94.24%	-32.78%	-61.46%
Average Drawdown Average peak-to-trough decline	-73.02%	-35.04%	-37.98%
Ulcer Index Depth and duration of drawdowns from previous peaks	53.28%	19.50%	+33.78%

Volatility

ARCT vs. MBX - Volatility Comparison

The current volatility for Arcturus Therapeutics Holdings Inc. (ARCT) is 19.67%, while MBX Biosciences, Inc (MBX) has a volatility of 23.40%. This indicates that ARCT experiences smaller price fluctuations and is considered to be less risky than MBX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARCT	MBX	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.67%	23.40%	-3.73%
Volatility (6M) Calculated over the trailing 6-month period	41.10%	57.78%	-16.68%
Volatility (1Y) Calculated over the trailing 1-year period	92.73%	133.96%	-41.23%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.85%	118.74%	-26.89%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	102.23%	118.74%	-16.51%

Dividends

ARCT vs. MBX - Dividend Comparison

Neither ARCT nor MBX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ARCT and MBX in my portfolio?

ARCT and MBX have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ARCT or MBX?

MBX has higher volatility (23.40%) compared to ARCT (19.67%). In terms of maximum drawdown, ARCT dropped -95.23% vs MBX's -77.71%.

Which has better risk-adjusted returns?

MBX currently has the higher Sharpe Ratio (1.17 vs -0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.